ITEMS IN AFP WITH KEYWORD:
Colchicine, 0.5 mg daily, significantly reduces the risk of myocardial infarction and ischemia-driven revascularization.
Dec 1, 2020 Issue
Beta Blockers for Suspected or Diagnosed Acute Myocardial Infarction [Cochrane for Clinicians]
Compared with placebo, beta-blocker use in patients with acute MI reduces short-term (less than three months) risk of MI and long-term (more than three months) risk of cardiovascular mortality and all-cause mortality.
Daily colchicine after MI reduces cardiovascular events, specifically strokes and hospitalizations for angina. It is inexpensive and well-tolerated and should be considered for patients with recent MIs who are already using guideline-directed therapy.
Jun 1, 2020 Issue
Supplemental Oxygen Therapy for Nonhypoxemic Patients with Acute Coronary Syndrome [FPIN's Clinical Inquiries]
No conclusive evidence demonstrates that routine use of supplemental oxygen therapy is associated with clinical benefit or harm in nonhypoxemic patients with acute myocardial infarction (MI).
Jun 15, 2019 Issue
Depression After ACS Events: AAFP Releases Updated Guidelines [Practice Guidelines]
The American Academy of Family Physicians has released a guideline focusing on depression in adults within three months of an ACS event (unstable angina or myocardial infarction). The guideline is based on a systematic review of randomized controlled trials and observational studies and covers screening and treatment.
Mar 1, 2019 Issue
Myocardial Infarction: Expert Consensus Group Provides Updated Definition [Practice Guidelines]
An expert consensus group of the European Society of Cardiology, American College of Cardiology Foundation, American Heart Association, and World Heart Federation has provided an updated universal definition of myocardial infarction.
The most useful element for ruling in acute MI is chest pain with radiation to both arms, followed by radiation to the right arm. The most useful elements for ruling out acute MI are pleuritic chest pain, sharp pain, and pain reproduced by palpation.
Cardiac troponin T and I are released into the bloodstream when cardiac muscle is damaged. Cardiac troponin tests have been available for decades and are the preferred biomarkers for the diagnosis of acute myocardial infarction (AMI). However, until recently, they lacked sensitivity in the first few hours following an acute myocardial injury.
Although recommended by guidelines and used as a so-called quality indicator of hospital care, the use of beta blockers following myocardial infarction, when combined with optimal acute and chronic treatment, does not provide a further survival benefit.